Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Lifted by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,320 shares of the biopharmaceutical company’s stock after acquiring an additional 13,422 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.06% of Alnylam Pharmaceuticals worth $20,165,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ALNY. Price T Rowe Associates Inc. MD boosted its position in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after buying an additional 201,784 shares during the period. Capital International Investors lifted its stake in shares of Alnylam Pharmaceuticals by 1.8% in the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after purchasing an additional 64,560 shares during the last quarter. Capital Research Global Investors boosted its position in Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after purchasing an additional 214,908 shares during the period. Bellevue Group AG grew its holdings in Alnylam Pharmaceuticals by 3.7% during the first quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock valued at $137,238,000 after purchasing an additional 32,966 shares during the last quarter. Finally, TD Asset Management Inc raised its position in shares of Alnylam Pharmaceuticals by 6.0% in the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock valued at $119,055,000 after purchasing an additional 27,592 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $248.79 on Thursday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a market cap of $32.09 billion, a P/E ratio of -94.96 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The business’s fifty day moving average is $273.83 and its two-hundred day moving average is $236.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the prior year, the business earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ALNY shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Barclays lifted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Chardan Capital restated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Finally, Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.